Key Insights The projected fair value for PepGen is US$14.23 based on 2 ... for patients with Duchenne muscular dystrophy (DMD) whose mutations are amenable to an exon 51-skipping approach.
a treatment for Duchenne muscular dystrophy or DMD in patients with exon 44 skipping amenable mutations. The company announced it has received authorization from the United Kingdom's Medicines and ...
Entrada Therapeutics has secured authorisation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to ...
patients with a mutation in the DMD gene amenable to exon 44 skipping. With this decision by U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA), which follows positive findings from a ...
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle ...
The Elevate-44-201 study is a global, two-part, randomized, double-blind placebo-controlled phase 1/2 study evaluating the ...
Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...
BOSTON - Entrada Therapeutics , Inc. (NASDAQ:TRDA) received authorization from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial for its ...
Treatment with oral therapy ifetroban led to improvements in measures of heart function in people with Duchenne muscular dystrophy (DMD), according to top-line results from a clinical trial. The ...
ROME, ITALY – JANUARY 23: Nuno Tavares of Lazio is challenged by Jon Mikel Aramburu of Real Sociedad during the UEFA Europa League 2024/25 League Phase MD7 match between S.S. Lazio and Real ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback